These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24755012)

  • 1. Clinical translation of nuclear export inhibitors in cancer.
    Senapedis WT; Baloglu E; Landesman Y
    Semin Cancer Biol; 2014 Aug; 27():74-86. PubMed ID: 24755012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
    Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
    Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
    Benkova K; Mihalyova J; Hajek R; Jelinek T
    Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
    Lai C; Xu L; Dai S
    Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XPO1-dependent nuclear export as a target for cancer therapy.
    Azizian NG; Li Y
    J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
    Parikh K; Cang S; Sekhri A; Liu D
    J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer.
    Sexton R; Mahdi Z; Chaudhury R; Beydoun R; Aboukameel A; Khan HY; Baloglu E; Senapedis W; Landesman Y; Tesfaye A; Kim S; Philip PA; Azmi AS
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
    Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
    Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
    Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
    Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding XPO1 target networks using systems biology and mathematical modeling.
    Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS
    Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
    Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
    EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
    Gerecitano J
    J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms.
    Balasubramanian SK; Azmi AS; Maciejewski J
    Leukemia; 2022 Mar; 36(3):601-612. PubMed ID: 35091658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The past, present, and future of CRM1/XPO1 inhibitors.
    Wang AY; Liu H
    Stem Cell Investig; 2019; 6():6. PubMed ID: 30976603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer.
    Mendonca J; Sharma A; Kim HS; Hammers H; Meeker A; De Marzo A; Carducci M; Kauffman M; Shacham S; Kachhap S
    Oncotarget; 2014 Aug; 5(15):6102-12. PubMed ID: 25026284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
    Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.